These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29736890)

  • 1. A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.
    Cheung SYA; Parkinson J; Wählby-Hamrén U; Dota CD; Kragh ÅM; Bergenholm L; Vik T; Collins T; Arfvidsson C; Pollard CE; Tomkinson HK; Hamrén B
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):365-381. PubMed ID: 29736890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs.
    Kågström J; Sjögren EL; Ericson AC
    J Pharmacol Toxicol Methods; 2007; 56(2):186-93. PubMed ID: 17582787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials.
    Kulesh V; Vasyutin I; Volkova A; Peskov K; Kimko H; Sokolov V; Alluri R
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):5-22. PubMed ID: 37950388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical to Clinical Translation of Hemodynamic Effects in Cardiovascular Safety Pharmacology Studies.
    Bhatt S; Northcott C; Wisialowski T; Li D; Steidl-Nichols J
    Toxicol Sci; 2019 May; 169(1):272-279. PubMed ID: 30726989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation.
    Authier S; Abernathy MM; Correll K; Chui RW; Dalton J; Foley CM; Friedrichs GS; Koerner JE; Kallman MJ; Pannirselvam M; Redfern WS; Urmaliya V; Valentin JP; Wisialowski T; Zabka TS; Pugsley MK
    Int J Toxicol; 2020; 39(4):274-293. PubMed ID: 32406289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced effects on cardiovascular function in pentobarbital anesthetized guinea-pigs: invasive LVP measurements versus the QA interval.
    Johnson DM; Geys R; Lissens J; Guns PJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):152-9. PubMed ID: 22813982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds.
    Marks L; Borland S; Philp K; Ewart L; Lainée P; Skinner M; Kirk S; Valentin JP
    Toxicol Appl Pharmacol; 2012 Sep; 263(2):171-83. PubMed ID: 22714037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model.
    Hauser DS; Stade M; Schmidt A; Hanauer G
    J Pharmacol Toxicol Methods; 2005; 52(1):106-14. PubMed ID: 15961325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development.
    Markert M; Shen R; Trautmann T; Guth B
    J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical cardiac safety assessment of drugs.
    Hanton G
    Drugs R D; 2007; 8(4):213-28. PubMed ID: 17596108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium.
    Sager P; Heilbraun J; Turner JR; Gintant G; Geiger MJ; Kowey PR; Mansoor GA; Mendzelevski B; Michelson EL; Stockbridge N; Weber MA; White WB
    Am Heart J; 2013 Apr; 165(4):477-88. PubMed ID: 23537963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?
    Laverty H; Benson C; Cartwright E; Cross M; Garland C; Hammond T; Holloway C; McMahon N; Milligan J; Park B; Pirmohamed M; Pollard C; Radford J; Roome N; Sager P; Singh S; Suter T; Suter W; Trafford A; Volders P; Wallis R; Weaver R; York M; Valentin J
    Br J Pharmacol; 2011 Jun; 163(4):675-93. PubMed ID: 21306581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Charge is an important determinant of hemodynamic and adverse cardiovascular effects of cationic drugs.
    Pugsley MK; Authier S; Curtis MJ
    Pharmacol Res; 2015 Dec; 102():46-52. PubMed ID: 26368292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future approaches to nonclinical cardiovascular safety assessment.
    Collins TA; Rolf MG; Pointon A
    Drug Discov Today; 2020 Jul; 25(7):1129-1134. PubMed ID: 32209428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report.
    Klein SK; Redfern WS
    J Pharmacol Toxicol Methods; 2015; 76():1-6. PubMed ID: 26126834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical power analysis of cardiovascular safety pharmacology studies in conscious rats.
    Bhatt S; Li D; Flynn D; Wisialowski T; Hemkens M; Steidl-Nichols J
    J Pharmacol Toxicol Methods; 2016; 81():128-35. PubMed ID: 27071954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
    Thai-Cuarto D; O'Brien CF; Jimenez R; Liang GS; Burke J
    Drug Saf; 2018 Apr; 41(4):429-440. PubMed ID: 29218680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
    Guo L; Dong Z; Guthrie H
    J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications.
    Brouillette J; Nattel S
    Can J Cardiol; 2017 Dec; 33(12):1577-1586. PubMed ID: 29173600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.